208 related articles for article (PubMed ID: 27761727)
21. HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma.
Oates J; Edwards C
Histopathology; 2000 Apr; 36(4):341-7. PubMed ID: 10759948
[TBL] [Abstract][Full Text] [Related]
22. Overexpression of Aquaporin-1 in lung adenocarcinomas and pleural mesotheliomas.
López-Campos JL; Sánchez Silva R; Gómez Izquierdo L; Márquez E; Ortega Ruiz F; Cejudo P; Barrot Cortés E; Toledo Aral JJ; Echevarría M
Histol Histopathol; 2011 Apr; 26(4):451-9. PubMed ID: 21360438
[TBL] [Abstract][Full Text] [Related]
23. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
Ordóñez NG
Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
[TBL] [Abstract][Full Text] [Related]
24. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung.
Di Loreto C; Puglisi F; Di Lauro V; Damante G; Beltrami CA
Cancer Lett; 1998 Feb; 124(1):73-8. PubMed ID: 9500194
[TBL] [Abstract][Full Text] [Related]
25. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
Attanoos RL; Thomas DH; Gibbs AR
Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
[TBL] [Abstract][Full Text] [Related]
26. Anti-mesothelial markers in sarcomatoid mesothelioma and other spindle cell neoplasms.
Attanoos RL; Dojcinov SD; Webb R; Gibbs AR
Histopathology; 2000 Sep; 37(3):224-31. PubMed ID: 10971698
[TBL] [Abstract][Full Text] [Related]
27. RhoA and vigilin are candidates for immunohistochemical markers for epithelioid malignant mesothelioma.
Hiratsuka T; Yamamoto T; Yoshizawa A; Toyokuni S; Tsuruyama T
Sci Rep; 2022 Nov; 12(1):18519. PubMed ID: 36323745
[TBL] [Abstract][Full Text] [Related]
28. Pleural mesothelioma in situ and its adenocarcinoma simulator.
Bono F
Int J Surg Pathol; 2010 Dec; 18(6):519-20. PubMed ID: 21081535
[No Abstract] [Full Text] [Related]
29. Tenascin XB Is a Novel Diagnostic Marker for Malignant Mesothelioma.
Nakayama K; Seike M; Noro R; Takeuchi S; Matsuda K; Kunugi S; Kubota K; Gemma A
Anticancer Res; 2019 Feb; 39(2):627-633. PubMed ID: 30711938
[TBL] [Abstract][Full Text] [Related]
30. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
31. M14K and M38K malignant pleural mesothelioma cell lines preserve the same claudin-based phenotype in vivo.
Chaouche-Mazouni S; Copin MC; Lassalle P; Lebaili N; Cortot A; Scherpereel A
In Vivo; 2013; 27(2):227-32. PubMed ID: 23422483
[TBL] [Abstract][Full Text] [Related]
32. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
33. miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
Cappellesso R; Galasso M; Nicolè L; Dabrilli P; Volinia S; Fassina A
Cancer Cytopathol; 2017 Aug; 125(8):635-643. PubMed ID: 28449331
[TBL] [Abstract][Full Text] [Related]
34. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study.
Ordóñez NG; Sahin AA
Hum Pathol; 2014 Jul; 45(7):1529-40. PubMed ID: 24816068
[TBL] [Abstract][Full Text] [Related]
36. TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma.
Bakir K; Koçer NE; Deniz H; Güldür ME
Ann Diagn Pathol; 2004 Dec; 8(6):337-41. PubMed ID: 15614737
[TBL] [Abstract][Full Text] [Related]
37. Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Bozdag Z; Tutar E; Dizibuyuk OF; Bakir K
Pathol Oncol Res; 2020 Jul; 26(3):1651-1656. PubMed ID: 31512057
[TBL] [Abstract][Full Text] [Related]
38. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Mar; 19(3):417-28. PubMed ID: 16415794
[TBL] [Abstract][Full Text] [Related]
39. SPARC Is a Novel Positive Immunohistochemical Marker of Epithelioid Mesothelioma to Differentiate It From Lung Adenocarcinoma and/or Squamous Cell Carcinoma.
Nakagiri T; Amatya VJ; Kushitani K; Kambara T; Aoe K; Endo I; Miyata Y; Okada M; Takeshima Y
Am J Surg Pathol; 2024 Feb; 48(2):140-149. PubMed ID: 37899530
[TBL] [Abstract][Full Text] [Related]
40. Calretinin as a blood-based biomarker for mesothelioma.
Johnen G; Gawrych K; Raiko I; Casjens S; Pesch B; Weber DG; Taeger D; Lehnert M; Kollmeier J; Bauer T; Musk AW; Robinson BWS; Brüning T; Creaney J
BMC Cancer; 2017 May; 17(1):386. PubMed ID: 28558669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]